At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $154.32M, above the global median of $18.58M
- FinancialsAltman Z-Score 0.7: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.58BCNY685.93M · vs all stocks (USD)
Revenue (TTM)
379.28MCNY56.82M · vs all stocks (USD)
Profit Margin
-2.76%Beta
0.2220xvs all stocks
52-Week Change
-56.24%vs all stocks
Market Capitalization
4.58BCNY685.93M · vs all stocks (USD)
Enterprise Value
7.81BCNY1.17B · vs all stocks (USD)
Forward P/E
4.32xPrice to Sales (TTM)
11.90xPrice to Book (MRQ)
0.7492xEnterprise to Revenue
20.60xEnterprise to EBITDA
-6.50xGross Margin
13.90%Profit Margin
-2.76%Operating Margin
-54.21%Return on Assets (TTM)
-7.57%Return on Equity (TTM)
-22.65%Revenue (TTM)
379.28MCNY56.82M · vs all stocks (USD)
Revenue per Share (TTM)
0.4040CNYUpdated Oct 23, 2026Quarterly Revenue Growth
-53.50%Gross Profit (TTM)
-663.69MCNY-99.42M · vs all stocks (USD)
EBITDA (TTM)
-1.20BCNY-179.94M · vs all stocks (USD)
Net Income (TTM)
-1.56BCNY-233.57M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-75.73%Operating Cash Flow (TTM)
487.29MCNY73.00M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
1.03BCNY154.32M · vs all stocks (USD)
5-Year Average Dividend Yield
0.59%vs all stocks
Payout Ratio
85.51%Minority Interest (Equity)
-1.74MCNYFY2025 · Dec 31, 2025Revenue
798.06MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
820.12MCNYFY2025 · Dec 31, 2025Gross Profit
-22.06MCNYFY2025 · Dec 31, 2025Operating Income
-417.86MCNY-62.60M · vs all stocks (USD)
Pre-tax Income
-1.63BCNYFY2025 · Dec 31, 2025Income Tax Expense
-257.47MCNYFY2025 · Dec 31, 2025Net Income
-1.37BCNYFY2025 · Dec 31, 2025EBIT
-1.49BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-257.53MCNYFY2025 · Dec 31, 2025Research & Development
46.35MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
185.25MCNYFY2025 · Dec 31, 2025Other Operating Expenses
38.65MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
37.01MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
139.00MCNYFY2025 · Dec 31, 2025EPS (Basic)
-1.45CNYFY2025 · Dec 31, 2025EPS (Diluted)
-1.45CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
939.84MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
939.84MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-1.37BCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
3.40MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-2.65BCNYFY2025 · Dec 31, 2025Free Cash Flow
-2.72BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
76.90MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-1.37BCNYFY2025 · Dec 31, 2025Other Non-cash Items
156.55MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-947.80MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-488.25MCNYFY2025 · Dec 31, 2025Capital Expenditures
-66.14MCNYFY2025 · Dec 31, 2025Purchase of Investments
-530.87MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-597.01MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.42BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.83BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-276.56MCNYFY2025 · Dec 31, 2025Other Financing Charges
-2.21MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-698.51MCNYFY2025 · Dec 31, 2025Shares Outstanding
940.86MSharesUpdated Oct 23, 2026Float Shares
443.56MSharesUpdated Oct 23, 2026% Held by Insiders
60.24%vs all stocks
% Held by Institutions
2.60%vs all stocks
Total Cash (MRQ)
69.12MCNY10.35M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0740CNYUpdated Oct 23, 2026Total Debt (MRQ)
3.14BCNY470.98M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5197xCurrent Ratio (MRQ)
1.31xBook Value per Share (MRQ)
6.41CNYUpdated Oct 23, 2026Total Assets
10.63BCNY1.59B · vs all stocks (USD)
Total Current Assets
5.15BCNYFY2025 · Dec 31, 2025Total Liabilities
4.36BCNYFY2025 · Dec 31, 2025Total Non-current Assets
5.49BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
269.57MCNYFY2025 · Dec 31, 2025Total Current Liabilities
4.09BCNYFY2025 · Dec 31, 2025Cash
76.90MCNYFY2025 · Dec 31, 2025Cash Equivalents
2.02MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
78.91MCNYFY2025 · Dec 31, 2025Other Short-term Investments
438.51KCNYFY2025 · Dec 31, 2025Accounts Receivable
2.55BCNYFY2025 · Dec 31, 2025Inventory
1.32BCNYFY2025 · Dec 31, 2025Accounts Payable
341.10MCNYFY2025 · Dec 31, 2025Short-term Debt
3.07BCNYFY2025 · Dec 31, 2025Other Current Liabilities
30.27MCNYFY2025 · Dec 31, 2025Long-term Debt
53.20MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
58.11MCNYFY2025 · Dec 31, 2025Common Stock (Book)
941.00MCNYFY2025 · Dec 31, 2025Retained Earnings
2.55BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
6.28BCNY940.62M · vs all stocks (USD)
Treasury Stock
13.89MCNYFY2025 · Dec 31, 202552-Week Low
4.21CNYUpdated Oct 23, 202652-Week High
11.95CNYUpdated Oct 23, 202652-Week Change
-56.24%vs all stocks
Beta
0.2220xvs all stocks
50-Day MA
5.49CNYUpdated Oct 23, 2026200-Day MA
6.61CNYUpdated Oct 23, 2026Avg 10-Day Volume
22.36MSharesUpdated Oct 23, 2026Avg 30-Day Volume
21.05MSharesUpdated Oct 23, 2026Diluted EPS (TTM)
-1.66CNYUpdated Oct 23, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 0.7: distress zoneCritical
Altman Z-Score: 0.70
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $154.32M, above the global median of $18.58MNotable
Levered free cash flow (USD): 154,318,524.058Global Median: 18,579,867.004
Companies that share the same coordination system — how they create, deliver, or capture value.
Yabao Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Wit Dyne Health Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Sunflower Great Health Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guizhou Sanli Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Luoxin Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Fuan Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
SWS Hemodialysis Care Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hunan Fangsheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Getein Biotech Inc.
Tier 1ProductionApproval-Gated PipelineRule
Center Laboratories, Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow